Borderline Personality Disorder (BPD)
Research into psychedelic-assisted therapies for Borderline Personality Disorder (BPD) indicates promising potential, particularly with compounds such as ketamine and MDMA, which may enhance emotional processing and neuroplasticity. However, systematic exclusion of BPD patients from psychedelic trials has limited available data, highlighting the need for dedicated research in this area.
Key Insights
- 1
BPD affects up to 2.7% of the population, significantly burdening healthcare systems.
- 2
Psychedelic therapies including ketamine and MDMA have been proposed to enhance emotional regulation and neural adaptability, crucial for BPD treatment.
- 3
Most current studies on psychedelics focus on comorbid conditions, rather than BPD itself, highlighting a research gap.
- 4
MDMA-assisted therapy shows promise for PTSD, which shares symptomatology with BPD, raising interest in its applicability for BPD populations.
- 5
Emerging studies suggest ketamine's potential benefits for suicidality and depression in individuals with BPD.
What is Borderline Personality Disorder (BPD)?
Borderline personality disorder (BPD) is a complex mental health condition characterised by profound instability in identity, relationships, and emotional regulation. Individuals with BPD often display impulsive behaviours, intense anger, chronic feelings of emptiness, suicidal ideation, and self-harm.
The pathophysiology of BPD is multifactorial, involving genetic predispositions, neurobiological dysregulation, and significant environmental stressors. Genetic factors may account for around 40% of the disorder's heritability, while neurochemical imbalances—particularly in serotonin systems—contribute to symptoms of mood instability and impulsivity.
Environmental factors such as childhood trauma, emotional neglect, and socioeconomic disadvantage are significant risk variables. BPD frequently co-occurs with other psychiatric conditions, diminishing treatment efficacy and complicating the clinical landscape.
Current Treatments
First-line treatment for BPD typically involves psychotherapy, primarily dialectical behaviour therapy (DBT) and mentalisation-based therapy (MBT). Medications may be prescribed for comorbid conditions but do not consistently improve core BPD features.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Borderline Personality Disorder (BPD).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ketamine Emerging studies indicate significant effects on mood and impulsivity; however, data specific to BPD is still sparse. | Large | Moderate | Inconsistent |
| MDMA Potential benefits inferred from PTSD treatments, but lack of direct research on BPD limits conclusions. | Medium | Low | Inconsistent |
| Psilocybin Highlights from PTSD research suggest potential, yet BPD-specific data remain undeveloped. | Medium | Low | Inconsistent |
Ketamine and Borderline Personality Disorder (BPD)
Ketamine acts as a non-competitive NMDA receptor antagonist, offering rapid antidepressant effects that may significantly benefit individuals with BPD, particularly those experiencing co-occurring depressive symptoms. Its unique mechanism may enhance neuroplasticity, addressing the emotional dysregulation core to BPD by facilitating reparative processes within dysfunctional neural circuits.
MDMA and Borderline Personality Disorder (BPD)
MDMA acts primarily on serotonin, dopamine, and norepinephrine systems, fostering emotional openness and reducing fear responses. Its potential utility in BPD stems from its ability to enhance therapeutic engagement during sessions, which may lead to profound emotional insights and improved interpersonal relationships, critical for addressing the instability characteristic of BPD.
Psilocybin and Borderline Personality Disorder (BPD)
Psilocybin primarily engages the 5-HT2A receptor, influencing emotional processing and cognitive flexibility. This compound holds promise for BPD as it may help individuals re-evaluate their emotional patterns and stabilize their sense of self, alongside promoting introspection during therapeutic experiences.
Clinical Outlook
The burgeoning field of psychedelic research offers potential new avenues for treating BPD, particularly as traditional therapies often fall short. Continued exploration into psychedelic-assisted therapies may unlock novel interventions targeting the unique challenges posed by BPD, although careful consideration of safety and efficacy will be crucial in the development of these treatments.
Industrial Landscape
Key players in the psychedelic space include Compass Pathways, which is developing psilocybin therapy for treatment-resistant depression, and MindMed, exploring LSD formulations for anxiety. Both companies have focused historically on populations outside of BPD due to safety concerns, with a growing call for more inclusive research practices.
Quick Indicators
Related Topics
Organisations
Search →University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation (MRO) headquartered in Madison, Wisconsin. Co-founded in 2014 by Bill Linton (CEO of Promega Corporation) and Malynn Utzinger, M.D., Usona was established after Linton witnessed the profound impact of a Johns Hopkins psilocybin study on a terminally ill friend. Unlike commercial drug developers, Usona operates as a mission-driven MRO — conducting and supporting pre-clinical and clinical research on psilocybin and other consciousness-expanding medicines, with the goal of developing accessible, affordable treatments. Its research leadership includes Dr. Charles Raison (Director of Clinical and Translational Research, UW-Madison psychiatrist) and Dr. Alexander Sherwood (medicinal chemist). Usona's psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study (the largest Phase 2 randomised controlled trial of psilocybin for MDD at the time), the Institute launched the Phase 3 uAspire trial in 2024 — a 240-participant, randomised, double-blind, multicentre study comparing 25 mg psilocybin vs placebo in adults with MDD. Usona is also exploring 5-MeO-DMT in early-stage research.
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
Federal University of Rio Grande do Norte (UFRN)
Federal University of Rio Grande do Norte is a public research university in Brazil with active neuroscience and mental health research programmes, including work linked to psychedelic science through affiliated institutes.
Shalvata Mental Health Center
Shalvata Mental Health Center is a 114-bed comprehensive psychiatric hospital founded in 1956 in Hod HaSharon, Israel, affiliated with Clalit Health Services and the Sackler Faculty of Medicine at Tel Aviv University; it is one of Israel's most active psychedelic research sites, having conducted trials comparing intranasal versus intravenous ketamine administration, MDMA-assisted psychotherapy for borderline personality disorder, and ketamine combined with cognitive behavioral analysis system of psychotherapy (CBASP) for chronic treatment-resistant depression.
University Hospital, Bonn
University hospital affiliated with the University of Bonn and one of Europe's leading academic medical centers. Its psychiatry and neuroscience departments have contributed to research on psychedelic-assisted therapies and novel treatments for mood and anxiety disorders.
People
Search →Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
Marta Valle
PhD; researcher/lecturer in Pharmacology, Therapeutics and Toxicology at Universitat Autònoma de Barcelona and associated researcher at Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
She is a key clinical psychopharmacology researcher on human ayahuasca studies, including neurophysiology, pharmacokinetics, and potential therapeutic effects on mindfulness and emotion regulation.
Juan Carlos Pascual
Psychiatrist and researcher at Hospital de la Santa Creu i Sant Pau / Universitat Autònoma de Barcelona
He is a notable clinical psychiatry researcher on ayahuasca, with published work on its effects on mindfulness, emotion regulation, self-compassion, and related therapeutic potential.
Elisabet Domínguez-Clavé
Psychologist, PhD in Pharmacology; clinician and researcher at Hospital de la Santa Creu i Sant Pau (Barcelona)
A leading Spanish ayahuasca and psychedelic researcher whose work has helped characterize post-acute, emotional-regulation, and mindfulness-related effects of ayahuasca.
Stephen Ross
Professor of Psychiatry
A leading clinical investigator who has advanced the application of psilocybin-assisted psychotherapy for cancer-related existential distress and substance use disorders through influential clinical trials and qualitative studies.
Rodrigo Mansur
Clinical Researcher in Affective Disorders
Notable for clinical research into psychedelic-assisted psychotherapy and rapid-acting antidepressant treatments for treatment-resistant mood disorders, with emphasis on translational and real-world effectiveness studies.
Fernanda Palhano-Fontes
Research Engineer at the Brain Institute, UFRN
Led the world's first double-blind, placebo-controlled trial of ayahuasca for treatment-resistant depression.
Franz Vollenweider
Professor Emeritus of Psychiatry
Key figure in brain imaging research and director of the Heffter Research Center Zurich.
Roger McIntyre
Professor of Psychiatry and Pharmacology at the University of Toronto
A global leader in mood disorder research and a pioneer in rapid-acting treatments like ketamine.
Amanda Feilding
Executive Director and Founder
Innocative figure in psychedelic research and founder of the Beckley Foundation.
Connected Evidence
The latest clinical data and verified academic findings associated with Borderline Personality Disorder (BPD).